SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
The Spectrum Pharmaceuticals class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum Pharmaceuticals had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, Spectrum Pharmaceuticals' public statements were materially false and misleading at all relevant times.SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers and acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period") have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit. The Spectrum Pharmaceuticals class action lawsuit charges Spectrum Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934. The Spectrum Pharmaceuticals class action lawsuit (Luo v. Spectrum Pharmaceuticals, Inc., No. 2:21-cv-01612) was commenced on August 31, 2021 and is pending in the District of Nevada.
聖迭戈，9月2021年7月/美通社/--Robbins Geller Rudman&Dowd LLP宣佈，Spectrum PharmPharmticals，Inc.(納斯達克市場代碼：SPPI)證券的購買者和收購者在2018年12月27日至2021年8月5日，(“上課期間”)可在2021年11月1日之前尋求任命為SPECTRUM製藥公司集體訴訟。這個SPECTRUM製藥公司集體訴訟指控Spectrum製藥公司及其某些高管違反了1934年的證券交易法。這個SPECTRUM製藥公司集體訴訟(羅訴斯派勒姆製藥公司(Lo v.Spectrum PharmPharmticals，Inc.)，編號2：21-cv-01612)於2021年8月31日目前正在內華達州地區待決。
If you wish to serve as lead plaintiff of the Spectrum Pharmaceuticals class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Spectrum Pharmaceutical class action lawsuit must be filed with the court no later than November 1, 2021.
如果你希望擔任該案件的主要原告，SPECTRUM製藥公司集體訴訟，請點擊此處提供您的信息。你也可以通過撥打800/449-4900或通過電子郵件聯繫羅賓斯·蓋勒律師J.C.桑切斯[受電子郵件保護]。首席原告動議SPECTRUM製藥公司集體訴訟必須不遲於向法院提起2021年11月1日.
CASE ALLEGATIONS: Spectrum Pharmaceuticals is a biopharmaceutical company whose products under development include, among others, ROLONTIS (eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. In December 2018, Spectrum Pharmaceuticals submitted a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for ROLONTIS as a treatment for chemotherapy-induced neutropenia (the "ROLONTIS BLA").
案件指控：SPECTRUM製藥公司是一家生物製藥公司，其正在開發的產品包括ROLONTIS(Eflapegrastim)，這是一種治療化療引起的中性粒細胞減少症的新型長效粒細胞集落刺激因子。2018年12月，Spectrum PharmPharmticals向美國食品和藥物管理局(FDA)提交了一份生物製品許可證申請(BLA)，申請ROLONTIS作為治療化療引起的中性粒細胞減少症(ROLONTIS BLA)的藥物。
The Spectrum Pharmaceuticals class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum Pharmaceuticals had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, Spectrum Pharmaceuticals' public statements were materially false and misleading at all relevant times.
這個SPECTRUM製藥公司集體訴訟稱，在整個集體期間，被告作出了虛假和誤導性的陳述，並且沒有披露：(I)ROLONTIS製造工廠維持着不完善的控制和/或程序；(Ii)上述缺陷降低了FDA批准目前形式的ROLONTIS BLA的可能性；(Iii)Spectrum PharmPharmticals因此嚴重誇大了ROLONTIS BLA的批准前景；(Iv)因此，Spectrum製藥公司的公開聲明是重大虛假的。
On August 6, 2021, Spectrum Pharmaceuticals announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and indicated that a reinspection of Spectrum Pharmaceuticals' manufacturing facility will be necessary. On this news, Spectrum Pharmaceuticals' stock price fell more than 21%, damaging investors.
2021年8月6日，Spectrum製藥公司宣佈收到FDA關於ROLONTIS BLA的完整回覆信(“CRL”)。CRL列舉了與製造有關的缺陷，並表示有必要對Spectrum製藥公司的製造設施進行重新檢查。這一消息傳出後，Spectrum PharmPharmticals的股價下跌了21%以上，損害了投資者的利益。
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Spectrum Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Spectrum Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Spectrum Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery of the Spectrum Pharmaceuticals class action lawsuit is not dependent upon serving as lead plaintiff.
主要原告程序：1995年私人證券訴訟改革法案允許任何在課堂期間購買Spectrum PharmPharmticals證券的投資者尋求被任命為首席原告SPECTRUM製藥公司集體訴訟。主要原告通常是在推定階級所尋求的救濟中具有最大經濟利益的動因，該推定階級也是推定階級中的典型和適當的。主要原告代表所有其他班級成員指示SPECTRUM製藥公司集體訴訟。主原告可以選擇自己選擇的律師事務所對SPECTRUM製藥公司集體訴訟。投資者在未來任何潛在的經濟復甦中分享的能力SPECTRUM製藥公司集體訴訟不依賴於擔任主要原告。
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions. Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors last year, more than double the amount recovered by any other securities plaintiffs' firm. Please visit http://www.rgrdlaw.com for more information.
關於羅賓斯·蓋勒·魯德曼律師事務所：Robbins Geller Rudman&Dowd LLP在全國9個辦事處擁有200名律師，是美國最大的證券集體訴訟投資者代理律師事務所。羅賓斯·蓋勒(Robbins Geller)的律師獲得了歷史上許多最大的股東追回，包括有史以來最大的證券集體訴訟追回-72億美元在Re Enron Corp.SEC.立蒂格。在2020年ISS證券集體訴訟服務50強報告中，羅賓斯·蓋勒在康復方面排名第一16億美元對於去年的投資者來説，這是任何其他證券原告公司追回的金額的兩倍多。如需更多信息，請訪問http://www.rgrdlaw.com。
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
律師廣告。過去的結果並不能保證未來的結果。我們任何一個辦事處的律師都可以提供服務。
Contact:
聯繫方式：
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]
羅賓斯·蓋勒·魯德曼律師事務所百老匯西655號，聖地亞哥信箱：CA 92101J.C.桑切斯，800-449-4900[受電子郵件保護]
SOURCE Robbins Geller Rudman & Dowd LLP
來源：Robbins Geller Rudman&Dowd LLP
Related Links
相關鏈接
http://rgrdlaw.com
Http://rgrdlaw.com
